BioSpace News Archive

Pharming Group N.V. announces that Pharming’s management will participate in the following investor conferences in the U.S. in the month of September.

CancerVAX, Inc announced that in a recent Company podcast its CEO, Ryan Davies, spoke with and UCLA cancer physician and researcher, Dr. Steven Jonas, about his journey to becoming both a practicing cancer doctor and active cancer researcher.

Synthego and bit.bio announced a strategic partnership to build a platform centered on the implementation of synthetic circuitry in cells for therapeutic application.

EDAP TMS SA, the global leader in robotic energy-based therapies, reported unaudited financial results for the second quarter ending June 30, 2023, and announced the appointment of Ryan Rhodes to the Board of Directors of the Company.

Bio-Techne Corporation announced that management will host its 2023 Investor Day on Friday, September 8, 2023, starting at 8:30 a.m. EDT.

Element Biosciences, Inc. announced the appointment of veteran life science executive Yaron Hakak as Senior Vice President of Corporate and Business Development.

Ginkgo Bioworks and the International Livestock Research Institute announced that they have entered into a Memorandum of Understanding with the intent to collaborate on pandemic surveillance work.

Bausch + Lomb Corporation announced expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended, with respect to the previously announced agreement to acquire XIIDRA 5%, a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease focusing on inflammation associated with dry eye, and certain other ophthalmology assets.

Xcell Biosciences Inc. (Xcellbio), an instrumentation company focused on cell and gene therapy applications, today announced it has achieved key milestones in its R&D collaboration with Labcorp, a global leader of innovative and comprehensive laboratory services, aimed at driving innovation in the development and validation of cell and gene therapies.

Aprea Therapeutics, Inc., a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, announced it has appointed Dr. Jean-Pierre Bizzari to its Board of Directors and is naming Dr. Richard Peters as its new Chairman of the Board.